Future Science Group
Browse
Supplementary Table 1.docx (55.33 kB)

Supplementary Table 1. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

Download (55.33 kB)
figure
posted on 2021-06-22, 08:28 authored by Nina Shah, Miguel-Angel Perales, Cameron J Turtle, Mitchell S Cairo, Andrew J Cowan, Hayder Saeed, Lihua E Budde, Alan Tan, Zachary Lee, Kazuharu Kai, Mario Q Marcondes, Jonathan Zalevsky, Mary A Tagliaferri, Krina K Patel
Supplementary Box 1. Eligibility criteria for a Phase 1 study of NKTR-255 as monotherapy, or in combination with daratumumab or rituximab, in hematologic malignancies

Funding

Nektar Therapeutics

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC